Cai Yuanxuan, Yang Linhui, Shangguan Xiaofang, Zhao Yuhang, Huang Rui
School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Pharmacol. 2021 Oct 20;12:736618. doi: 10.3389/fphar.2021.736618. eCollection 2021.
Cephalosporins are widely used in clinical treatment of children, but it is difficult to carry out clinical trials and there is no strong evidence of their safety. Therefore, adverse drug reactions (ADR) of cephalosporins can be a public health problem that deserves attention. ADR reports collected by the Hubei Adverse Drug Reaction Monitoring Center from 2014 to 2019 were analysed. The safety of Cephalosporins was described by descriptive analysis and three signal mining methods, including the reporting odd ratio (ROR), proportional reporting ratio (PRR), and comprehensive standard method (MHRA). The findings indicated that the age groups of 0-1 and 2-3 years had the highest rates of reporting ADRs. Children aged 0-4 years reported more ADRs, while the proportion of severe ADRs was lower than the average (6.63%). Among the 37 cephalosporins, the severe ADRs of ceftezole, ceftazidime, cefoperazone/sulbactam, cefotaxime, ceftriaxone were reported more and the proportion of severe ADRs was higher. The proportion of severe ADRs of most cephalosporin compound preparations was higher than that of corresponding single components. A total of 99.18% of the cases improved after treatment. There were four deaths whose ADRs were mainly anaphylactic shock, dyspnoea, and anaphylactoid reaction. In signal mining, the three methods produced 206 signals that were the same, and 73 of them were off-label ADRs. ADRs were common but not serious in children aged 0-4 years. And the reported rate of serious ADRs in children aged over 4 years increased with age. ADR reports of ceftezole, ceftazidime, cefoperazone/sulbactam, cefotaxime, ceftriaxone were numerous and serious, and the safety of cephalosporin compound preparations in children was doubtful. Ceftezole may cause off-label ADRs including tremor, face oedema, cyanosis, pallor, rigors, and palpitation. The labeling of ADRs in children in cephalosporin instructions and the record of allergic history need to be improved.
头孢菌素在儿童临床治疗中广泛应用,但开展临床试验困难且缺乏有力的安全性证据。因此,头孢菌素的药物不良反应(ADR)可能成为一个值得关注的公共卫生问题。对湖北省药品不良反应监测中心2014年至2019年收集的ADR报告进行了分析。通过描述性分析和三种信号挖掘方法(包括报告比值比(ROR)、比例报告比值(PRR)和综合标准法(MHRA))来描述头孢菌素的安全性。研究结果表明,0至1岁和2至3岁年龄组的ADR报告率最高。0至4岁儿童报告的ADR较多,而严重ADR的比例低于平均水平(6.63%)。在37种头孢菌素中,头孢唑林、头孢他啶、头孢哌酮/舒巴坦、头孢噻肟、头孢曲松的严重ADR报告较多且严重ADR比例较高。大多数头孢菌素复方制剂的严重ADR比例高于相应的单一组分。共有99.18%的病例治疗后好转。有4例死亡,其ADR主要为过敏性休克、呼吸困难和类过敏反应。在信号挖掘中,三种方法产生了206个相同的信号,其中73个为超说明书用药ADR。ADR在0至4岁儿童中常见但不严重。4岁以上儿童严重ADR的报告率随年龄增长而增加。头孢唑林、头孢他啶、头孢哌酮/舒巴坦、头孢噻肟、头孢曲松的ADR报告数量多且严重,头孢菌素复方制剂在儿童中的安全性存疑。头孢唑林可能导致超说明书用药ADR,包括震颤、面部水肿、发绀、苍白、寒战和心悸。头孢菌素说明书中儿童ADR标注及过敏史记录有待完善。